Drug Profile


Alternative Names: ARRY-520

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Class Amides; Antineoplastics; Fluorobenzenes; Small molecules; Thiadiazoles
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • No development reported Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 03 Dec 2016 Safety and efficacy data from a phase Ib/II trial in Multiple myeloma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 31 May 2016 Array Biopharma completes a phase-II clinical trials for Multiple myeloma (combination therapy, second-line therapy or greater) in USA (IV) (NCT01989325)
  • 02 May 2016 Array BioPharma completes a phase I trial for multiple myeloma in USA (NCT01248923)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top